TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04236037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided pleural biopsy
Description: Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracentesis
Description: The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracentesis
Description: The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
Study: NCT00243919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early locomotor training program
Description: The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late locomotor training program
Description: The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
Study: NCT02873767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR1
Description: * Active substance: UCB4019~* Route of Administration: subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR1
Description: * Active substance: UCB4019~* Route of Administration: subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR1
Description: * Active substance: UCB4019~* Route of Administration: subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR1
Description: * Active substance: UCB4019~* Route of Administration: subcutaneously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PL1
Description: * Active substance: Placebo~* Concentration: 0.9 % saline~* Route of Administration: subcutaneously
Study: NCT03089463

Intervention type: DIAGNOSTIC_TEST
Intervention: Observation
Description: The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
Study: NCT04746469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed automated phone call
Description: Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
Study: NCT04240808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCD19 CAR T Cells
Description: Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector \[LV\] Transduced Autologous Peripheral Blood Lymphocytes)
Study: NCT02359461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination pulsatile Stendo3
Study: NCT01905150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-FLIP
Description: G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-FLIP
Description: G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
Study: NCT02359461

Intervention type: DEVICE
Group type: OTHER
Intervention: Combination pulsatile Stendo3
Study: NCT04343352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implementation of mobile epilepsy training program
Description: Mobile epilepsy training program will be applied to the application group for 3 months.~The mobile epilepsy training program developed within the scope of the thesis will be introduced to the parents in the application group and the participants will be uploaded to their phones via computer, and the use of the program will be taught in practice. In addition, the participants in the application group will be informed that the mobile epilepsy training program is not open to everyone during the research process, only the application group can use it. After the work is completed, the mobile application control group will be installed on the phones of the parents via computer, their application will be taught and applied.
Study: NCT01954589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 1500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almorexant 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02532504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT
Description: 8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~1. Five Areas vicious circle~2. Bad thought spotter~3. Amazing Bad thought Busting Programme (ABTPB)~4. Easy 4 Step plan~5. Things you do that mess you up/Confidence sheet~6. Happy List/ Things you do that boost how you feel sheet~7. Planner and Review sheets
Study: NCT01905150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-FLIP-DM
Description: G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-FLIP-DM
Description: G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
Study: NCT00703300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT02157519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Intervention
Description: Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Study: NCT02238730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrabrief Right Unilateral
Description: The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pulse Bitemporal
Description: The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
Study: NCT01749956

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Study: NCT04548544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Awareness, Resilience, and Action (TARA)
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
Study: NCT03410004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
Study: NCT03749317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIEW-1201
Description: IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
Study: NCT03947697

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (Sensory)
Description: Group will receive Electrical Stimulation up to sensory level

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (Sensory)
Description: Group will receive Electrical Stimulation up to sensory level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Group will receive Electrical Stimulation up to maximum tolerable level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Group will receive Electrical Stimulation up to maximum tolerable level

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Group will receive exercise training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Group will receive exercise training.
Study: NCT04352998

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: One dose pre-workout condition
Description: one dose of a multi-ingredient pre-workout supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Two dose pre-workout condition
Description: two doses of a multi-ingredient pre-workout supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo condition
Description: one dose of a placebo
Study: NCT02330289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normative report card
Description: Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
Study: NCT02417077

Intervention type: OTHER
Intervention: Photographic Review
Description: Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
Study: NCT04245943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 18 weeks supervised strength and aerobic exercise training.
Study: NCT02299089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide FluidCrystal® injection depot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide FluidCrystal® injection depot
Study: NCT03150836

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
Study: NCT03862248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6EH³RZ
Description: New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6EHR³Z
Description: New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6EHRZLfx
Description: WHO levofloxacin-strengthened regimen (6EHRZLfx)
Study: NCT02586766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Sync
Description: A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
Study: NCT00525590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIADEL
Description: Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
Study: NCT05875688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cementation Technique A
Description: * Use of adequate amount of cement.~* Prevention of wastage of cement.~* Retention of crowns for longer duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cementation Technique B
Description: * Use of Sufficient Cement Quantity.~* Keeping cement from going to waste.~* Increased time that crowns remain in place.
Study: NCT03509168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Pfizer Brand
Description: insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally

Intervention type: OTHER
Group type: OTHER
Intervention: Non-insertion of Misoprostol Pfizer Brand
Description: participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
Study: NCT00380536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Health Education Class
Description: Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
Study: NCT03199352

Intervention type: OTHER
Intervention: RYGB hand-sewn
Description: Patients will have the RYGB anastomosis hand-sewn

Intervention type: OTHER
Intervention: RYGB linear-staple
Description: Patients will have the RYGB anastomosis performed using a linear staple.
Study: NCT00749398

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: According to local country regulations.
Study: NCT03401047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
Study: NCT00994305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600 mg bid po 0-7 PO

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control
Description: No treatment: standard care provided. No N-acetylcysteine administration.
Study: NCT03506048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given orally once daily continuously
Study: NCT01666483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-laparoscopy
Description: M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoendoscopic single site surgery
Description: LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
Study: NCT04319393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling
Study: NCT02343224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b
Description: PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
Study: NCT03573635

Intervention type: DEVICE
Group type: OTHER
Intervention: Supratube
Description: Aspiration of orotracheal secretions with supratube device

Intervention type: OTHER
Group type: OTHER
Intervention: Reference
Description: Usual aspiration with any other device
Study: NCT02623712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: More Frequent Surveillance Strategy
Description: Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Less Frequent Surveillance Strategy
Description: Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.